ACW ASX · Health Care

Actinogen Medical Ltd

Announcements, last 12 months: 114
Price sensitive, last 12 months: 27
Followed on InvestorPA: Some (top 20% of companies)

Latest announcements

Released	Headline	Actions
21 Oct 2026, 8:55 AM	ACW pivotal Alzheimers trial database lock - results mid-Nov Price sensitive	AI summary
19 Oct 2026, 9:57 AM	ACW September 2026 quarterly activity report & Appendix 4C Price sensitive	AI summary
12 Oct 2026, 12:41 PM	Notification of buy-back - ACW
9 Oct 2026, 9:10 AM	AGM date and closing date for director nominations
30 Sep 2026, 1:04 PM	Application for quotation of securities - ACW
23 Sep 2026, 12:35 PM	Options underwriting cleansing notice
23 Sep 2026, 12:35 PM	Application for quotation of securities - ACW
23 Sep 2026, 12:34 PM	Underwriting of unlisted options completed Price sensitive	AI summary
23 Sep 2026, 8:47 AM	ACW Alzheimers pivotal trial completes last patient visit Price sensitive	AI summary
16 Sep 2026, 12:43 PM	Notification of cessation of securities - ACW

Sign in to see all ACW announcements.

Guidance history

19 Oct 2026	Actinogen expects topline results from the XanaMIA trial in November 2026.
1 Sep 2026	Approximately $4.77 million additional funding from underwriting agreement
27 Aug 2026	Net loss after tax for FY2026 was $15,379,848; R&D costs were $19,027,365.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow ACW to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.